About us
Research Library
Company Pages
Allergy Therapeutics
ANGLE
Arecor Therapeutics
Avacta
Futura Medical
HUTCHMED
MaxCyte
Nexstim
Redx Pharma
Scancell
Contact us
More Company News
Arecor Therapeutics
First patient dosed in Cohort 2 of the ModiFY Phase I clinical trial
16 Aug 2022
Read More
Arecor Therapeutics
Q222 results
10 Aug 2022
Read More
Arecor Therapeutics
First participant in IMG-004 Phase I trial
09 Aug 2022
Read More
Arecor Therapeutics
EU patents for biosimilar Humira formulations
09 Aug 2022
Read More
Arecor Therapeutics
SAVANNAH shows 49% ORR in high MET lung cancer
08 Aug 2022
Read More
Arecor Therapeutics
FRESCO-2 meets primary endpoint in mCRC
08 Aug 2022
Read More
Arecor Therapeutics
H122 interim results & business update
01 Aug 2022
Read More
Arecor Therapeutics
Tazemetostat China bridging study in r/r FL starts
01 Aug 2022
Read More
Arecor Therapeutics
Result of placing
01 Aug 2022
Read More
Arecor Therapeutics
Proposed acquisition of Tetris Pharma Ltd
01 Aug 2022
Read More
1
2
3
4
…
66
Return to Arecor Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).
About us
Research Library
Company Pages
▼
Allergy Therapeutics
ANGLE
Arecor Therapeutics
Avacta
Futura Medical
HUTCHMED
MaxCyte
Nexstim
Redx Pharma
Scancell
Contact us